Log in

NYSE:IQV - Iqvia Stock Price, Forecast & News

$144.85
-0.44 (-0.30 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$144.42
Now: $144.85
$146.78
50-Day Range
$137.59
MA: $144.79
$149.56
52-Week Range
$104.90
Now: $144.85
$164.13
Volume1.16 million shs
Average Volume1.18 million shs
Market Capitalization$28.11 billion
P/E Ratio28.29
Dividend YieldN/A
Beta0.87
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.41 billion
Cash Flow$11.17 per share
Book Value$34.76 per share

Profitability

Net Income$259 million

Miscellaneous

Employees58,000
Market Cap$28.11 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.


Iqvia (NYSE:IQV) Frequently Asked Questions

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) released its earnings results on Wednesday, October, 30th. The medical research company reported $1.60 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.57 by $0.03. The medical research company earned $2.77 billion during the quarter, compared to the consensus estimate of $2.76 billion. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The company's revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.42 EPS. View Iqvia's Earnings History.

When is Iqvia's next earnings date?

Iqvia is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Iqvia.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia updated its fourth quarter earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of $1.65-1.75 for the period, compared to the Thomson Reuters consensus estimate of $1.75. The company issued revenue guidance of $2.807-2.857 billion, compared to the consensus revenue estimate of $2.89 billion.

What price target have analysts set for IQV?

18 analysts have issued 1-year price objectives for Iqvia's stock. Their forecasts range from $136.38 to $180.00. On average, they anticipate Iqvia's stock price to reach $166.46 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Iqvia.

What is the consensus analysts' recommendation for Iqvia?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Has Iqvia been receiving favorable news coverage?

News headlines about IQV stock have been trending very positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Iqvia.

Are investors shorting Iqvia?

Iqvia saw a decline in short interest in November. As of November 29th, there was short interest totalling 3,550,000 shares, a decline of 5.6% from the November 14th total of 3,760,000 shares. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is currently 2.5 days. Currently, 2.0% of the shares of the stock are sold short. View Iqvia's Current Options Chain.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), Allergan (AGN), Athabasca Oil (ATH), Honeywell International (HON), Paypal (PYPL) and Accenture (ACN).

Who are Iqvia's key executives?

Iqvia's management team includes the folowing people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

Who are Iqvia's major shareholders?

Iqvia's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.78%), TPG Group Holdings SBS Advisors Inc. (3.05%), Third Point LLC (1.03%), USS Investment Management Ltd (0.75%), Boston Partners (0.56%) and Russell Investments Group Ltd. (0.44%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

Which institutional investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Boston Partners, USS Investment Management Ltd, First Trust Advisors LP, Chilton Investment Co. LLC, Nomura Holdings Inc., Assenagon Asset Management S.A. and Man Group plc. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

Which institutional investors are buying Iqvia stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Third Point LLC, Orbimed Advisors LLC, Banco Santander S.A., Mackay Shields LLC, JS Capital Management LLC, State of New Jersey Common Pension Fund D and California Public Employees Retirement System. View Insider Buying and Selling for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $144.85.

How big of a company is Iqvia?

Iqvia has a market capitalization of $28.11 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

What is Iqvia's official website?

The official website for Iqvia is http://www.iqvia.com/.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]


MarketBeat Community Rating for Iqvia (NYSE IQV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  469 (Vote Outperform)
Underperform Votes:  420 (Vote Underperform)
Total Votes:  889
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel